| Objective To investigate the effect of NMDA2B subunit antagonist Ro25-6981onpain in the tibial cancer rats by studing the spinal JAK/STAT3,NMDA/NOS pathway.Themethods of real-time PCR, Western-Blot, ELISA and Immunohistochemistry were used inthis research and the cross-talk in whole level（immune and sensing system）,celllevel（microglia and astrocyte） and molecular level （expression of NR2B, JAK2,GFAP andSTAT3acceptors; conternt of NOS, NO,IL-6and GLU） was tested to dicuss the effectand mechanism of NR2B subunit in rats of tibial cancer.Methods Twenty-four female SDrats weighing180～220g were randomly divided into4groups：Sham group， Modelgroup，Ro25-6981group and AG490group was respectively received intrathecal injectionof0.9%saline20μl, Ro25-698120μl（5μg/μl） or AG49050μg, The rat model of bonecancer pain was produced by intra-tibial injection of Walker-256tumor cell. Painthreshold was estimated by measuring paw withdrawal response to compressionstimulation on the0,1,3，7and14day．The expression changes of GFAP, STAT3and NR2B were detected by immunohistochemistry method．Results：In R, M and A groupsPWPT was significantly decreased compared with Sham group，the staining of GFAP andSTAT3immuno-reactive cells were heavier and the average areas were significantlylargerthan that in Sham group（p<0．O5）．In R and A group Pwpt was significantlyincreased compared with group M．In R and A group staining of GFAP and STAT3immuno-reactive cells were lighter and the average areas were significantly smaller thanthat in group M （P<0．05）．Conclusion pre-emptive Low dose Ro256981can attenuate thecancer pain by inhibiting the activation ofJAK/STAT3pathway and gliocyte in spinal cord. |
